Breakthrough ‘Protein Paint’ Enables Early Detection of Alzheimer’s adn Other Dementias
A revolutionary new technique developed by chemists at Utrecht University promises earlier and more accurate diagnosis of Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. For teh first time, scientists can directly measure the growth of harmful protein clumps – even in blood – offering a potential turning point in the fight against thes devastating neurological conditions.
The core challenge in treating dementia lies in its insidious onset. The damaging processes in the brain begin years, even decades, before noticeable symptoms like memory loss appear. By the time a diagnosis is made, meaningful and often irreversible damage has already occurred, limiting the effectiveness of interventions. Developing new medications is similarly hampered by the difficulty of tracking disease progression in its earliest stages.
Now, a team led by chemists Françoise Dekker, Júlia Aragonès Pedrola, and Stefan Rüdiger, along with international collaborators, has unveiled a method that effectively “paints” proteins, making the earliest stages of protein aggregation visible and quantifiable. Their research, published in the Proceedings of the National Academy of Sciences, centers around a family of molecules called FibrilPaint.
These molecules are designed to bind specifically to amyloid fibrils – the long, thread-like protein structures that accumulate in the brains of dementia patients. Crucially, FibrilPaint is also fluorescent, emitting light when analyzed with specialized equipment.This allows researchers to not only visualize the fibrils but also measure their size, providing a direct indication of disease progression. “We could already see such fibrils under an electron microscope, but this method is not suitable to monitor body fluids,” explained Stefan Rüdiger, Professor of Protein Chemistry of Disease at Utrecht University. “with FibrilPaint, we can now follow their growth step by step in liquid form.”
The technique offers a significant advantage over existing methods, which frequently enough require extensive pre-treatment of samples before protein analysis. FibrilPaint can be used directly on blood or cerebrospinal fluid, streamlining the diagnostic process. Initial experiments demonstrate FibrilPaint’s ability to lower the end-plateau in ThT assays in a dose-dependent manner, confirming its binding affinity to TauRD protein aggregates. Further analysis using Flow induced Dispersion Analysis (FIDA) shows that when fibrilpaint binds to fibrils, it increases the perceived size of the species, allowing for accurate measurement. Binding curves indicate a Kd of 1.6E−6 for FibrilPaint1 with TauRD fibrils, demonstrating a strong binding affinity.
The implications for drug progress are substantial. According to Dekker, “With our technique, we will soon be able to monitor the progression of the disease much more precisely and determine whether a treatment is effective.” The team has already established a start-up, NeuroTidal Diagnostics, to translate FibrilPaint into a practical diagnostic tool for clinical trials.
The journey to this breakthrough wasn’t without obstacles. Rüdiger revealed that the initial concept for FibrilPaint was rejected for a major research grant three years ago, deemed too ambitious. Undeterred, he persevered, securing alternative funding and ultimately realizing his vision. “Reaching this point now feels like a real milestone,” he stated.
This innovative approach represents a significant leap forward in our ability to understand, diagnose, and ultimately combat the devastating effects of dementia. more facts about the research can be found in the article, “FibrilPaint to determine the length of Tau amyloids in fluids,” published in proceedings of the National Academy of Sciences (DOI: 10.1073/pnas.2502847122).
